PT1745064E - Compostos para a inibição de uma enzima de proteassoma - Google Patents

Compostos para a inibição de uma enzima de proteassoma Download PDF

Info

Publication number
PT1745064E
PT1745064E PT05735686T PT05735686T PT1745064E PT 1745064 E PT1745064 E PT 1745064E PT 05735686 T PT05735686 T PT 05735686T PT 05735686 T PT05735686 T PT 05735686T PT 1745064 E PT1745064 E PT 1745064E
Authority
PT
Portugal
Prior art keywords
quot
alkyl
compound
mmol
compound according
Prior art date
Application number
PT05735686T
Other languages
English (en)
Portuguese (pt)
Inventor
John H Musser
Mark S Smyth
Guy J Laidig
Ronald T Borchardt
Barry A Bunin
Craig M Crews
John Clifford Chabala
Original Assignee
Proteolix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1745064(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Proteolix Inc filed Critical Proteolix Inc
Publication of PT1745064E publication Critical patent/PT1745064E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
PT05735686T 2004-04-15 2005-04-14 Compostos para a inibição de uma enzima de proteassoma PT1745064E (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US56234004P 2004-04-15 2004-04-15
US56909604P 2004-05-07 2004-05-07
US59940104P 2004-08-06 2004-08-06
US61000204P 2004-09-14 2004-09-14
US61000104P 2004-09-14 2004-09-14
US61015904P 2004-09-14 2004-09-14
US62057304P 2004-10-20 2004-10-20

Publications (1)

Publication Number Publication Date
PT1745064E true PT1745064E (pt) 2011-03-23

Family

ID=34965899

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05735686T PT1745064E (pt) 2004-04-15 2005-04-14 Compostos para a inibição de uma enzima de proteassoma

Country Status (17)

Country Link
US (9) US8129346B2 (OSRAM)
EP (1) EP1745064B1 (OSRAM)
JP (3) JP5616569B2 (OSRAM)
CN (2) CN103554222A (OSRAM)
AT (1) ATE494298T1 (OSRAM)
AU (1) AU2005238445B2 (OSRAM)
BE (1) BE2016C014I2 (OSRAM)
BR (1) BRPI0509879A (OSRAM)
CA (1) CA2562411A1 (OSRAM)
CY (1) CY1117244T1 (OSRAM)
DE (1) DE602005025750D1 (OSRAM)
DK (1) DK1745064T3 (OSRAM)
IL (3) IL178400A (OSRAM)
PL (1) PL1745064T3 (OSRAM)
PT (1) PT1745064E (OSRAM)
SG (2) SG185306A1 (OSRAM)
WO (1) WO2005105827A2 (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
AU2012203602B2 (en) * 2004-04-15 2015-08-27 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
JP5616569B2 (ja) 2004-04-15 2014-10-29 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 酵素阻害のための化合物
CN102875642A (zh) 2004-05-10 2013-01-16 普罗特奥里克斯公司 用于酶抑制的化合物
PL2260835T3 (pl) 2004-12-07 2013-08-30 Onyx Therapeutics Inc Kompozycja do hamowania proteasomu
AU2006311584B2 (en) 2005-11-09 2012-03-08 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
CN101506224B (zh) * 2006-06-19 2016-03-30 欧尼斯治疗公司 蛋白酶体抑制用的肽环氧酮
PT2207791T (pt) 2007-10-04 2016-07-12 Onyx Therapeutics Inc Inibidores da epoxi cetona protease de péptido cristalino e a síntese de ceto-epóxidos de aminoácidos
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
AU2010225426B2 (en) * 2009-03-16 2015-09-03 The Governing Council Of The University Of Toronto Cyclic amino acid molecules and methods of preparing the same
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
GB0914883D0 (en) 2009-08-26 2009-09-30 Univ Belfast Compound
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
WO2011109355A1 (en) 2010-03-01 2011-09-09 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
JP2013525282A (ja) 2010-04-07 2013-06-20 オニキス セラピューティクス， インク． 結晶質ペプチドエポキシケトンイムノプロテアソーム阻害剤
HRP20240724T1 (hr) * 2012-05-08 2024-08-30 Onyx Therapeutics, Inc. Postupci kompleksiranja ciklodekstrina za formuliranje peptidnih inhibitora proteasoma
TW201414751A (zh) 2012-07-09 2014-04-16 歐尼克斯治療公司 肽環氧酮蛋白酶抑制劑之前驅藥物
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
MX373308B (es) 2013-03-13 2020-04-20 Sanofi Sa Composiciones que comprenden anticuerpos anti-cd38 y carfilzomib.
MX372671B (es) 2013-07-19 2020-04-23 Onyx Therapeutics Inc Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres.
CN103360348B (zh) * 2013-07-25 2015-06-24 苏州鹏旭医药科技有限公司 一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
CA2920220A1 (en) * 2013-09-06 2015-03-12 Sandoz Ag Synthesis of peptide epoxy ketones
CN105517998A (zh) * 2013-09-06 2016-04-20 桑多斯股份公司 通过曼尼希反应立体选择性合成二醇和三醇以及它们在卡非佐米合成中的用途
CN104710507B (zh) * 2013-12-11 2018-08-14 深圳翰宇药业股份有限公司 一种卡非佐米的制备方法
WO2015121769A1 (en) 2014-02-13 2015-08-20 Ranbaxy Laboratories Limited Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate
CN105960399B (zh) * 2014-07-14 2018-09-25 宁波圣健生物医药科技有限公司 酶抑制剂环氧酮化合物
US10329325B2 (en) 2014-09-24 2019-06-25 Biophore India Pharmaceuticals Pvt. Ltd Process for the preparation of (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxo-pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
WO2016069479A1 (en) 2014-10-27 2016-05-06 Apicore Us Llc Methods of making carfilzomib and intermediates thereof
CN107548400A (zh) 2014-12-02 2018-01-05 费森尤斯卡比肿瘤学有限公司 卡非佐米的纯化方法
EP3240575A4 (en) 2014-12-31 2018-07-25 Dr. Reddy's Laboratories Ltd. Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
WO2016116882A2 (en) * 2015-01-23 2016-07-28 Leiutis Pharmaceuticals Pvt Ltd Novel compositions of carfilzomib
WO2016170544A1 (en) * 2015-04-22 2016-10-27 Msn Laboratories Private Limited Process for the preparation of (2s)-n-((s)-1-((s)-4-methyl-1-((r)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((s)-2-(2-morpholino acetamido)-4-phenylbutanamido)-4-methylpentanamide
WO2016170489A1 (en) 2015-04-24 2016-10-27 Fresenius Kabi Oncology Ltd. Pharmaceutical compositions of proteasome inhibitor
US10364269B2 (en) * 2015-05-21 2019-07-30 Laurus Labs Limited Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
JP6961586B2 (ja) 2015-11-11 2021-11-05 ジーランド ファーマ エイ／エス α４β７インテグリンを標的とする環状ペプチド
EP3494126A1 (en) 2016-08-02 2019-06-12 Synthon BV Process for making carfilzomib
WO2018051237A1 (en) 2016-09-14 2018-03-22 Fresenius Kabi Oncology Limited A process for purification of carfilzomib intermediate
WO2018085921A1 (en) 2016-11-11 2018-05-17 Encycle Therapeutics, Inc. CYCLIC PEPTIDES MULTIMERS TARGETING α4β7 INTEGRIN
EP3330260A1 (en) 2016-12-01 2018-06-06 Enantia, S.L. Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib
CN106946981B (zh) * 2017-03-08 2020-08-21 南京陵瑞医药科技有限公司 一种四肽环氧丙烷衍生物及其制备方法和用途
CN110891964A (zh) 2017-05-10 2020-03-17 循环治疗学公司 靶向α4β7整合素的均环肽
BR112020005079A2 (pt) 2017-09-14 2020-09-15 Glaxosmithkline Intellectual Property Development Limited tratamento de combinação para câncer
CN113185575B (zh) * 2021-05-11 2022-07-12 四川大学 一种花生抗氧化多肽及其制备方法
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
JP2025516629A (ja) 2022-05-11 2025-05-30 セルジーン コーポレーション Ｔ細胞療法に関連する方法および使用、ならびにその生成
EP4611798A1 (en) 2022-11-02 2025-09-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
JPH01136498A (ja) 1987-11-21 1989-05-29 Nec Corp 状態監視用情報伝送装置
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5441944A (en) * 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
US5071957A (en) * 1989-08-04 1991-12-10 Bristol-Myers Company Antibiotic BU-4061T
US4990448A (en) 1989-08-04 1991-02-05 Bristol-Myers Company Bu-4061T
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH05506777A (ja) 1990-03-05 1993-10-07 セファロン、インコーポレーテッド キモトリプシン様プロテアーゼ及びそれらの阻害剤
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
GB9300048D0 (en) 1993-01-04 1993-03-03 Wellcome Found Endothelin converting enzyme inhibitors
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
AU4499697A (en) 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
DK0932617T3 (da) * 1996-10-18 2002-04-22 Vertex Pharma Inhibitorer af serinproteaser, især af hepatitis C-virus-NS3-protease
SI0932617T1 (en) 1996-10-18 2002-06-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
CA2274789A1 (en) 1996-12-13 1998-06-18 Zymogenetics, Inc. Compositions and methods for stimulating bone growth
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
AU750207B2 (en) * 1997-06-13 2002-07-11 Cydex Pharmaceuticals, Inc. Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof
US6099851A (en) * 1998-06-02 2000-08-08 Weisman; Kenneth M. Therapeutic uses of leuprolide acetate
US6838436B1 (en) * 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) * 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
CA2347275C (en) * 1998-10-20 2010-03-09 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en) * 1999-05-12 2004-12-14 Yale University Enzyme inhibition
AU784304B2 (en) * 1999-10-20 2006-03-09 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US20040106539A1 (en) * 2000-10-12 2004-06-03 Ulrich Schubert Agents for the treatment of viral infections
EP1463719A2 (en) * 2002-01-08 2004-10-06 Eisai Co., Ltd Eponemycin and epoxomicin analogs and uses thereof
EP1496916A2 (en) * 2002-04-09 2005-01-19 Greenville Hospital System Metastasis modulating activity of highly sulfated oligosaccharides
US20030224469A1 (en) * 2002-06-03 2003-12-04 Buchholz Tonia J. Methods and kits for assays utilizing fluorescence polarization
JP5616569B2 (ja) * 2004-04-15 2014-10-29 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 酵素阻害のための化合物
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US20050256324A1 (en) * 2004-05-10 2005-11-17 Proteolix, Inc. Synthesis of amino acid keto-epoxides
CN102875642A (zh) * 2004-05-10 2013-01-16 普罗特奥里克斯公司 用于酶抑制的化合物
CA2584515A1 (en) 2004-10-20 2006-04-27 Proteolix, Inc. Labeled compounds for proteasome inhibition
PL2260835T3 (pl) * 2004-12-07 2013-08-30 Onyx Therapeutics Inc Kompozycja do hamowania proteasomu
WO2006099261A2 (en) 2005-03-11 2006-09-21 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
AU2006311584B2 (en) 2005-11-09 2012-03-08 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
AR057227A1 (es) 2005-12-09 2007-11-21 Centocor Inc Metodo para usar antagonistas de il6 con inhibidores del proteasoma
DE102006026464A1 (de) * 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
CN101506224B (zh) * 2006-06-19 2016-03-30 欧尼斯治疗公司 蛋白酶体抑制用的肽环氧酮
JP4325683B2 (ja) * 2007-02-14 2009-09-02 セイコーエプソン株式会社 画像表示装置、及び画像表示装置の制御方法
WO2008140782A2 (en) 2007-05-10 2008-11-20 Proteolix, Inc. Compounds for enzyme inhibition
PT2207791T (pt) 2007-10-04 2016-07-12 Onyx Therapeutics Inc Inibidores da epoxi cetona protease de péptido cristalino e a síntese de ceto-epóxidos de aminoácidos
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones

Also Published As

Publication number Publication date
EP1745064B1 (en) 2011-01-05
US20120277146A1 (en) 2012-11-01
HK1097860A1 (en) 2007-07-06
US8207127B2 (en) 2012-06-26
JP2008501637A (ja) 2008-01-24
JP2012041346A (ja) 2012-03-01
US20120094926A1 (en) 2012-04-19
WO2005105827A3 (en) 2006-03-30
DE602005025750D1 (de) 2011-02-17
IL217210A0 (en) 2012-01-31
CN102174076A (zh) 2011-09-07
CA2562411A1 (en) 2005-11-10
US8207125B2 (en) 2012-06-26
US8207124B2 (en) 2012-06-26
WO2005105827A2 (en) 2005-11-10
US20120094930A1 (en) 2012-04-19
EP1745064A2 (en) 2007-01-24
IL178400A (en) 2012-02-29
BRPI0509879A (pt) 2007-10-16
US8324174B2 (en) 2012-12-04
SG185306A1 (en) 2012-11-29
BE2016C014I2 (OSRAM) 2024-10-09
US8129346B2 (en) 2012-03-06
US20120094928A1 (en) 2012-04-19
SG152239A1 (en) 2009-05-29
JP2014012676A (ja) 2014-01-23
AU2005238445B2 (en) 2012-05-03
AU2005238445A1 (en) 2005-11-10
US8207297B2 (en) 2012-06-26
IL217211A0 (en) 2012-01-31
CY1117244T1 (el) 2017-04-05
CN103554222A (zh) 2014-02-05
US20120101050A1 (en) 2012-04-26
PL1745064T3 (pl) 2011-06-30
ATE494298T1 (de) 2011-01-15
IL178400A0 (en) 2007-02-11
US20120094929A1 (en) 2012-04-19
US20120101048A1 (en) 2012-04-26
US8207126B2 (en) 2012-06-26
US20130324459A1 (en) 2013-12-05
DK1745064T3 (da) 2011-04-11
JP5616569B2 (ja) 2014-10-29
US20080200398A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
PT1745064E (pt) Compostos para a inibição de uma enzima de proteassoma
ES2674277T3 (es) Compuestos para la inhibición enzimática de proteosoma
PT1948678E (pt) Compostos para inibição de enzimas
IL179020A (en) Inhibitors of enzymes
ES2358268T3 (es) Compuestos para la inhibición enzimática de proteasoma.
ES2359004T3 (es) Compuestos para inhibición enzimática de proteasoma.
HK1097860B (en) Compounds for proteasome enzyme inhibition
AU2012211349A1 (en) Compounds for enzyme inhibition
AU2012201520A1 (en) Compounds for enzyme inhibition